Dupilumab Safe, Effective Over 5 Years in Moderate-Severe AD

TOPLINE: Over 5 years, dupilumab demonstrated acceptable safety and sustained efficacy, with significant improvements in the signs and symptoms of AD, in the treatment of moderate to severe atopic dermatitis (AD). METHODOLOGY: The phase 3 multinational LIBERTY AD open-label extension study evaluated the safety and efficacy of dupilumab in 2677 adults with moderate to severe ...

Get In Touch

479, Nuri Street 29

+6012 345 6495

mainportfolios@gmail.com

Follow Us
Flickr Photos

Copyright © 2024 fu.ci. All Rights Reserved